Catherine Lee is Director of R&D and Business Development at TAHO Pharmaceuticals Ltd., where she integrates over two decades of pharmaceutical research and development experience with strategic business acumen to drive innovation and global growth. She leads multidisciplinary teams across formulation development, regulatory strategy, and external collaboration, with a focus on advancing TAHO’s proprietary drug delivery technologies. As a co-inventor of TAHO’s core drug delivery platform, Catherine has been instrumental in the scientific design, optimization, and translational development of the company’s transdermal and transmucosal systems. Under her leadership, the platform has progressed from early formulation stages through process scale-up and toward commercialization. The result is a versatile and scalable technology capable of addressing a range of therapeutic needs. Her technical expertise encompasses oral, transdermal, and transmucosal formulations across key therapeutic areas, including CNS, metabolic disorders, cardiovascular disease, gastrointestinal conditions, and oncology. At Bio 2025, Catherine will present TAHO’s platform innovations and actively engage with potential partners to advance collaborative development and market expansion.